The return volley is almost always a smear job, and it’s easy to see why. Medical device company Penumbra (NYSE: PEN)‘s November 12th peak valuation of $9.9 billion was achieved in large part through the effective work of internal and external sales desks. That isn’t to say that the company’s reputation as an innovative operator … Continue reading Battlestar Penumbra: A Field Guide To The Ongoing Conflict